Loading company…
Basel biopharmaceutical company developing small molecule therapies for neurodegenerative diseases and cancer.
The Genetics Company Inc. develops small molecule biopharmaceutical products for neurodegenerative diseases such as Alzheimer's disease and for cancers, including colorectal cancer. Its pipeline includes Wnt-inhibitors, BACE1 inhibitors and small molecule cancer growth inhibitors, sold to healthcare providers and pharmaceutical partners. Headquartered in Basel, Switzerland, it raised CHF 8 million in the second tranche of its Series C funding in 2007, co-led by Nextech Invest and Novartis Venture Funds, and has completed 7 deals.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in